Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2026)

Puma Biotechnology (PBYI) has 10 years of Cost of Revenue data on file, last reported at $10.4 million in Q1 2026.

• Quarterly Cost of Revenue fell 1.25% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (down 9.66% YoY) and the FY2025 annual result came in at $58.2 million, down 9.7% from the prior year.
• Cost of Revenue retreated to $10.4 million in Q1 2026, from $23.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $29.1 million in Q3 2024 to a low of $10.4 million in Q1 2026.
• A 5-year average of $14.8 million and a median of $12.5 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue plunged 63.31% — and 2024, when it surged 119.04%.
• Tracing PBYI's Cost of Revenue over 5 years: stood at $16.8 million in 2022, then surged by 44.47% to $24.3 million in 2023, then plunged by 42.77% to $13.9 million in 2024, then soared by 66.13% to $23.1 million in 2025, then sank by 54.93% to $10.4 million in 2026.
• The last three Cost of Revenue figures came in at $10.4 million (Q1 2026), $23.1 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.